The promise of de­sign­er mi­crobes in­spires a $130M mega-round for Zymer­gen

These days, promis­ing a tech rev­o­lu­tion can be worth a for­tune in ven­ture back­ing. And that’s just what Zymer­gen just earned in its Se­ries B, which topped out at a mega-round sized $130 mil­lion.

This biotech com­pa­ny is en­gi­neer­ing de­sign­er mi­crobes, look­ing to cre­ate a whole new gen­er­a­tion of ma­te­ri­als that can be used in every­thing from gener­ic drugs to…well, you name it: cups, ad­he­sives, pro­teins and on and on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER